GE HealthCare Technologies Inc.

Company facts

Industry

X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Headquarters

Chicago, Illinois

Most recent report

8-K, filed Aug 18, 2026

Incorporated

Delaware

Filings on record

439 filings

On EDGAR

CIK 1932393

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 13 sections worth reading, with 2 positive, 4 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Core results, segment weakness, major acquisition, litigation, tariff refunds.
  Notable

  • Intelerad acquired for $2,293M cash in March 2026, funded by debt and cash on hand.
  • Iraqi Ministry of Health litigation: parties now in discovery after Court of Appeals denied en banc review.
  • Received $107M in IEEPA tariff refunds, recorded $38M receivable, $106M pre-tax benefit in Q2 2026.

• Management's Discussion (Item 2)

  Tariffs materially impact results; PCS segment in decline; segment restructuring.
  Positive

  • AIS (new segment) revenue grew 7.9% in Q2 2026 to $3,771M; organic growth 5.0% driven by cardio and CT.
  • PDx revenue grew 15.6% in Q2 2026 to $843M; organic growth 14.6% driven by volume and price in contrast media.
  Notable

  • Company spent $2,293M on Intelerad acquisition in H1 2026, a major strategic investment.
  Negative

  • Tariffs cut operating income by $68M in Q2 2026 and $156M in H1 2026, with ongoing material risk.
  • Russia/Ukraine assets $190M as of June 30, 2026; H1 revenue down to $106M from $123M due to sanctions.
  • PCS revenue fell 13.3% in Q2 2026 to $675M; segment EBIT swung from $60M profit to $26M loss.
  • China H1 revenue down 0.6% amid increased local competition and volume-based procurement.

What changed: Jun 2026 vs. Mar 2026

About 13% of GEHC's Jun 2026 10-Q is new information. 50 paragraphs were added, 152 changed, and 32 removed. Below are the most important lines SECSift identified.

• Item 2 83
• Item 1 57
• Item 4 2
• Item 6 1